The Effects of Preoperative Bevacizumab on Perioperative Complications

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT04788381
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.

Study Details

This is a nationwide multicenter,retrospective,observational real-world study. 1. To assess the risk of perioperative complications in patients with tumor who received bevacizumab prior to unexpected operation. 2. To assess the correlation of the interval time between the last dose of bevacizumab and operation and occurrence of perioperative complications. 3. To explore the risk factors of perioperative comlications in patients with tumor received bevacizumab prior to unexpected operation.

Key Dates

First listed
Mar 9, 2021
Start date
Apr 1, 2021
Status verified
Mar 2021
Primary completion
May 31, 2021
Completion
Jul 31, 2021

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Participants with CRC or lung cancer was performed unexpected operation
    This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.

Primary Outcome Measure

To assess the risk of perioperative complications in patients with tumor who received bevacizumab prior to unexpected operation. [ Time Frame: 30 days after operation ]

Central Contacts

Related Studies